In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

The missed PDUFA adds to a string of delays at the FDA in recent weeks, including at least two other missed target action ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

UK pharma major GSK (LSE: GSK) has published results from its Phase III MATINEE trial evaluating Nucala (mepolizumab) in ...

GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine ...

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...